Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (151-160 of 252) with videos related to

Pageof 26
Sort By:
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|October 26, 2017
Gastrojejunostomy versus duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancerYukio Yoshida, Akira Fukutomi, Masaki Tanaka, et al.
Journal of Gastroenterology|May 8, 2002
Carcinoma of duodenum arising from Brunner's glandKimishige Akino, Yoshihiro Kondo, Atsumori Ueno, et al.
BMC Cancer|July 25, 2020
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancerMasaaki Miyo, Takeshi Kato, Takayuki Yoshino, et al.
Cancers|November 14, 2023
Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)Takeshi Kajiwara, Tomohiro Nishina, Riu Yamashita, et al.
Medical Oncology (Northwood, London, England)|January 3, 2012
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, et al.
The Lancet. Oncology|September 7, 2012
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialTakayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki, et al.
Cancer Science|October 7, 2016
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210GKohei Shitara, Kimio Yonesaka, Tadamichi Denda, et al.
Medicine|September 9, 2020
Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III studyAyumu Hosokawa, Kentaro Yamazaki, Chu Matsuda, et al.
International Journal of Clinical Oncology|June 25, 2025
Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancerSatoshi Suzuki, Tomoya Yokota, Akifumi Notsu, et al.
International Journal of Clinical Oncology|February 25, 2011
Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aortaHiroya Taniguchi, Kentaro Yamazaki, Narikazu Boku, et al.
Pageof 26

Showing results (151-160 of 252) with videos related to

Sort By:
Pageof 26
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|October 26, 2017
Gastrojejunostomy versus duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancerYukio Yoshida, Akira Fukutomi, Masaki Tanaka, et al.
Journal of Gastroenterology|May 8, 2002
Carcinoma of duodenum arising from Brunner's glandKimishige Akino, Yoshihiro Kondo, Atsumori Ueno, et al.
BMC Cancer|July 25, 2020
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancerMasaaki Miyo, Takeshi Kato, Takayuki Yoshino, et al.
Cancers|November 14, 2023
Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)Takeshi Kajiwara, Tomohiro Nishina, Riu Yamashita, et al.
Medical Oncology (Northwood, London, England)|January 3, 2012
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, et al.
The Lancet. Oncology|September 7, 2012
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialTakayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki, et al.
Cancer Science|October 7, 2016
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210GKohei Shitara, Kimio Yonesaka, Tadamichi Denda, et al.
Medicine|September 9, 2020
Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III studyAyumu Hosokawa, Kentaro Yamazaki, Chu Matsuda, et al.
International Journal of Clinical Oncology|June 25, 2025
Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancerSatoshi Suzuki, Tomoya Yokota, Akifumi Notsu, et al.
International Journal of Clinical Oncology|February 25, 2011
Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aortaHiroya Taniguchi, Kentaro Yamazaki, Narikazu Boku, et al.
Pageof 26